(Hypertension. 2001;37:250.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
Hypothesis: ß-Adrenergic Receptor Blockers and Weight Gain
A Systematic Analysis
From the Franz Volhard Clinic and Max Delbrück Center for Molecular Medicine, Medical Faculty of the Charité, Humboldt University, Berlin, Germany.
Correspondence to Arya M. Sharma, MD, Franz Volhard Clinic, Wiltbergstrasse 50,13125, Berlin, Germany. E-mail sharma{at}fvk-berlin.de
One
of the arguments put forward against the primary use of ß-blockers
has been concern about adverse metabolic effects, such as
unfavorable effects on lipids or insulin sensitivity. Another
less-appreciated potential drawback is their propensity to cause weight
gain in some patients. In 8 evaluable prospective randomized controlled
trials that lasted 
6 months, body weight was higher in the
ß-blocker than in the control group at the end of the study. The
median difference in body weight was 1.2 kg (range -0.4 to 3.5 kg). A
regression analysis suggested that ß-blockers were associated
with an initial weight gain during the first few months. Thereafter, no
further weight gain compared with controls was apparent. There was no
relationship between demographic characteristics and changes in body
weight. Based on these observations, the first-line use of ß-blockers
in obese hypertensive patients should be reviewed. Obesity management
in overweight hypertensive patients may be more difficult in the face
of ß-blocker treatment.
Key Words: obesity • ß-blockers • body weight • hypertension, obesity
This article has been cited by other articles:
 |
|
 |
|
  F. H. Messerli, S. Bangalore, and S. Julius Risk/Benefit Assessment of {beta}-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension Circulation, May 20, 2008; 117(20): 2706 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mancia and G. Grassi Editorial: The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 5 - 12. [PDF]
|
|
|
|
 |
|
 I. Biaggioni Should We Target the Sympathetic Nervous System in the Treatment of Obesity-Associated Hypertension? Hypertension, February 1, 2008; 51(2): 168 - 171. [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Prevost Pharmacy Review: Lifestyle Management of Obesity: Considerations for Pharmacists American Journal of Lifestyle Medicine, December 1, 2007; 1(6): 451 - 453. [Abstract] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
 |
|
 W.S. Leslie, C.R. Hankey, and M.E.J. Lean Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review QJM, July 1, 2007; 100(7): 395 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
|
|
B. Williams The Obese Hypertensive: The Weight of Evidence Against {beta}-Blockers Circulation, April 17, 2007; 115(15): 1973 - 1974. [Full Text] [PDF]
|
|
|
|
|
|
J. Scholze, E. Grimm, D. Herrmann, T. Unger, and U. Kintscher Optimal Treatment of Obesity-Related Hypertension: The Hypertension-Obesity-Sibutramine (HOS) Study Circulation, April 17, 2007; 115(15): 1991 - 1998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N TENTOLOURIS, S LIATIS, and N KATSILAMBROS Sympathetic System Activity in Obesity and Metabolic Syndrome Ann. N.Y. Acad. Sci., November 1, 2006; 1083(1): 129 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Malone Medications Associated with Weight Gain Ann. Pharmacother., December 1, 2005; 39(12): 2046 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cabassi, P. Coghi, P. Govoni, E. Barouhiel, E. Speroni, S. Cavazzini, A. M. Cantoni, R. Scandroglio, and E. Fiaccadori Sympathetic Modulation by Carvedilol and Losartan Reduces Angiotensin II-Mediated Lipolysis in Subcutaneous and Visceral Fat J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2888 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Sharma Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension? Hypertension, July 1, 2004; 44(1): 12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Seals and C. Bell Chronic Sympathetic Activation: Consequence and Cause of Age-Associated Obesity? Diabetes, February 1, 2004; 53(2): 276 - 284. [Abstract] [Full Text]
|
|
|
|
|
|
J.-L. Ardilouze, B. A. Fielding, J. M. Currie, K. N. Frayn, and F. Karpe Nitric Oxide and {beta}-Adrenergic Stimulation Are Major Regulators of Preprandial and Postprandial Subcutaneous Adipose Tissue Blood Flow in Humans Circulation, January 6, 2004; 109(1): 47 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aneja, F. El-Atat, S. I. McFarlane, and J. R. Sowers Hypertension and Obesity Recent Prog. Horm. Res., January 1, 2004; 59(1): 169 - 205. [Abstract] [Full Text]
|
|
|
|
|
|
F. H Messerli The LIFE study: the straw that should break the camel's back Eur. Heart J., March 2, 2003; 24(6): 487 - 489. [Full Text] [PDF]
|
|
|
|
|
|
A. L. Birkenfeld, C. Schroeder, M. Boschmann, J. Tank, G. Franke, F. C. Luft, I. Biaggioni, A. M. Sharma, and J. Jordan Paradoxical Effect of Sibutramine on Autonomic Cardiovascular Regulation Circulation, November 5, 2002; 106(19): 2459 - 2465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Sharma and S. Engeli Managing big issues on lean evidence: treating obesity hypertension Nephrol. Dial. Transplant., March 1, 2002; 17(3): 353 - 355. [Full Text] [PDF]
|
|
|
|
|
|
F. H. Messerli, E. Grossman, and J. R. Sowers Diabetes, Hypertension, and Cardiovascular Disease: An Update Response Hypertension, September 1, 2001; 38 (3): e11 - e11. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Kumpusalo, J. K. Takala, and A. M. Sharma Do {beta}-Blockers Put on Weight? Response Hypertension, July 1, 2001; e5(1): . [Full Text] [PDF]
|
|